The collaboration agreement is summarized as follows
The collaborator retains ownership of any data and
subsequent research results generated by the collaborator.
Genomine retains ownership of any data and other
results generated by Genomine scientists.
The collaborator and Genomine will
work together to publish and patent results from
the collaboration. To avoid jeopardizing patentability,
each party will provide proposed publications (manuscripts,
presentations, etc) to the other party for approval
30 days prior to submission for publication.
The collaborator will notify Genomine
of any inventions it makes as a result of the collaboration.
Genomine will cover all patent costs for inventions
of interest to Genomine.
The collaborator and Genomine each
get to use all results and IP from the collaboration
for research purposes.
Genomine gets a first right to
negotiate a commercial license to any new IP resulted
from collaboration and solely owned by the collaborator.
For jointly owned IP, Genomine has the right to
use it non-exclusively for commercial purposes but
also has an option to negotiate an exclusive commercial
license. Genomine has a limited period of time within
which to notify the collaborator of its interest
in obtaining a license. For all commercial licenses
for Genomine, the parties will agree in good faith
on a reasonable financial return to the collaborator.
|